Immunogenic compositions
AssigneeThe Scripps Research Institute
InventorsWilliam R. SCHIEF, Torben SCHIFFNER, Jon M. STEICHEN, Xiaozhen HU
Life of this patent
Estimating the term…
Abstract
Provided herein are glycan engineered SARS-CoV-2 RBD polypeptides, fusion polypeptides comprising thereof, and immunogenic compositions comprising thereof. Also provided are methods of administering the RBD polypeptide, fusion polypeptide or immunogenic composition to a subject to elicit an immune response. Also provided are polynucleotides encoding the fusion polypeptide, and methods of administering a composition comprising the polynucleotide to a subject to elicit an immune response. In some embodiments, the polynucleotide is an RNA comprising modified ribonucleotides.
Claims127
A fusion polypeptide comprising
- a) at least one viral polypeptide comprising a SARS-CoV spike protein (S), a SARS-CoV-2 spike protein (S), or an immunogenic fragment thereof;
- and
- b) an amino acid sequence that targets the fusion polypeptide to the cell surface or a self-assembling domain capable of forming a nanoparticle.
Dependencies are inferred from the claim text.